Cassava Sciences Q2 2025 net loss $44.2M, including $31.25M litigation reserve; shifts focus to TSC epilepsy

FILANA THERAPEUTICS, INC.

2025-Q2 EPS reported -$1.40

Net loss $44.2M ($0.92 per share) vs net income $6.2M in Q2 2024.
Recorded $31.25M estimated loss contingency for securities litigation settlement.
Alzheimer's program phased out; new focus on simufilam for TSC-related epilepsy - PoC study expected H1 2026.
Cash $112.4M at June 30, 2025; H2 2025 net cash use $47-51M including litigation reserve.
Appointed Dr. Hulihan (CMO), Dr. Bordey (SVP Neuroscience), Dr. Moore (SVP Clin Dev).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.